Phase 3 Alzheimer's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 55 to 95 who live either in their own home in the community or in a care facility such as a nursing home or assisted living
• People who have been diagnosed with possible or probable Alzheimer's disease based on recognised medical guidelines (the 2011 NIA-AA criteria)
• People who have psychosis symptoms linked to a major or mild thinking and memory disorder, as defined by international guidelines (IPA criteria)
• People who have evidence of Alzheimer's-related changes in the brain, shown through a blood test, a brain scan (such as a PET scan), or fluid taken from around the spine
• People who have had a brain scan (MRI or CT) whose results are in line with an Alzheimer's disease diagnosis
• People whose score on a standard memory and thinking test (called the MMSE) falls between 6 and 24
• People who have been experiencing psychosis symptoms (such as hallucinations or unusual beliefs) for at least 2 months
• People who have a stable living situation with no planned changes to where they live
• People who have a designated caregiver or support person able to assist throughout the study
• People who are taking a stable dose of certain Alzheimer's medications (such as a cholinesterase inhibitor or memantine), if those medications have been prescribed

Who may not be able to join:

• People who need to take a medication that is not permitted under the trial's rules
• People who are in hospice or end-of-life palliative care, or who are no longer able to get out of bed
• People who require skilled nursing care
• People whose psychosis symptoms are mainly caused by delirium, substance use, or a medical or mental health condition other than dementia
• People with a known history of a brain blood vessel condition called cerebral amyloid angiopathy, epilepsy, a brain tumour, or unexplained episodes of fainting
• People with atrial fibrillation (an irregular heartbeat condition)
• People with symptomatic orthostatic hypotension (low blood pressure that causes dizziness or fainting when standing up)
• People whose blood test results at screening fall outside the ranges allowed by the trial's rules
• People who have received anti-tau therapy or a specific Alzheimer's drug called donanemab within the 2 months before the screening visit

Important: Additional eligibility criteria apply that are not listed here. Always verify eligibility with the trial site directly before applying.